Synapse

← Paul M. Ridker

Papers by Paul M. Ridker

Page 2 · newest first

  1. Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic RiskJournal of the American College of Cardiology · 2018
  2. Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With RosuvastatinJournal of the American College of Cardiology · 2011
  3. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coinEuropean Heart Journal · 2016
  4. Inflammation in AtherosclerosisJournal of the American College of Cardiology · 2009
  5. C-reactive protein and cardiovascular risk in the general populationEuropean Heart Journal · 2025
  6. High-sensitivity C-reactive protein: just measure it!European Journal of Preventive Cardiology · 2025
  7. Unsupervised Learning Analysis of Triglycerides, Inflammation, Cholesterol, and the Risks of Incident Cardiovascular Disease and Type 2 Diabetes in the Women's Health StudyJournal of the American Heart Association · 2025
  8. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’European Heart Journal · 2025
  9. Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarctionIJC Heart & Vasculature · 2025
  10. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trialObesity · 2025
  11. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementEuropean Heart Journal · 2025
  12. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk studyEuropean Heart Journal · 2025
  13. Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsJACC Advances · 2025
  14. Statin effects on immunoglobulin-G glycomic architecture and the link to cardiovascular disease2025
  15. Expanding the triglyceride range in clinical trials: therapeutic opportunitiesEuropean Heart Journal · 2025
  16. Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β BlockadeJACC Advances · 2025
  17. GWAS of CRP response to statins further supports the role of APOE in statin response: A GIST consortium studyPharmacological Research · 2025
  18. Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular riskLara D. Veeken · 2024
  19. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-AnalysisCirculation · 2024
  20. Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical TrialsNEJM Evidence · 2024
  21. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in WomenNew England Journal of Medicine · 2024
  22. Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II TrialEuropean Heart Journal · 2024
  23. Lessons from PROMINENT and prospects for pemafibrateCardiovascular Diabetology · 2024
  24. Transcriptome-wide association study and Mendelian randomization in pancreatic cancer identifies susceptibility genes and causal relationships with type 2 diabetes and venous thromboembolismEBioMedicine · 2024
  25. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trialsAtherosclerosis · 2024
  26. Interleukin-6 and Cardiovascular Events in Healthy AdultsJACC Advances · 2024
  27. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trialArthritis Research & Therapy · 2024
  28. Low-dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals with Chronically Treated HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes · 2024
  29. One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER TrialArteriosclerosis Thrombosis and Vascular Biology · 2024
  30. Mediterranean Diet Adherence and Risk of All-Cause Mortality in WomenJAMA Network Open · 2024
  31. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialNature Medicine · 2024
  32. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traitsNature Genetics · 2024
  33. Low-dose colchicine for atherosclerosis: long-term safetyEuropean Heart Journal · 2024
  34. A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin MedicationJournal of the American College of Cardiology · 2024
  35. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionNew England Journal of Medicine · 2024
  36. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIJournal of the American College of Cardiology · 2024
  37. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysisThe Lancet Diabetes & Endocrinology · 2024
  38. Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in WomenClinical Chemistry · 2024
  39. N-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular EventsCirculation Research · 2024
  40. Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study2024
  41. Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implicationsView · 2024
  42. Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trialBlood Advances · 2023
  43. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin IntoleranceCirculation · 2023
  44. Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trialAging Cell · 2023
  45. The Mediterranean Diet, Cardiometabolic Biomarkers, and Risk of All-Cause Mortality: A 25-Year Follow-Up Study of the Women’s Health Study2023
  46. Effect Measure Modification by Covariates in Mediation: Extending Regression-based Causal Mediation AnalysisEpidemiology · 2023
  47. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant PatientsJAMA · 2023
  48. Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudyArteriosclerosis Thrombosis and Vascular Biology · 2023
  49. Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trialBMC Infectious Diseases · 2023
  50. C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease LocationsThe American Journal of Cardiology · 2023